within Pharmacolibrary.Drugs.ATC.J;

model J01XX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.00010666666666666667,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.040799999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 840
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XX08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Linezolid is a synthetic antibiotic of the oxazolidinone class. It is primarily used to treat infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Linezolid is approved for clinical use and commonly prescribed for pneumonia, skin and soft tissue infections, and other severe bacterial infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers aged 18-55 years after single and multiple dosing (oral and intravenous administration), both sexes.</p><h4>References</h4><ol><li><p>Ubals, M, et al., &amp; Mitjà, O (2024). Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. <i>The Lancet. Infectious diseases</i> 24(4) 404–416. DOI:<a href=\"https://doi.org/10.1016/S1473-3099(23)00683-7\">10.1016/S1473-3099(23)00683-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38211601/\">https://pubmed.ncbi.nlm.nih.gov/38211601</a></p></li><li><p>Sicard, M, et al., &amp; Guen, CG (2015). Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. <i>European journal of clinical pharmacology</i> 71(5) 611–615. DOI:<a href=\"https://doi.org/10.1007/s00228-015-1813-3\">10.1007/s00228-015-1813-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25740677/\">https://pubmed.ncbi.nlm.nih.gov/25740677</a></p></li><li><p>Bassetti, M, et al., &amp; Giacobbe, DR (2022). Current pharmacotherapy for methicillin-resistant . <i>Expert opinion on pharmacotherapy</i> 23(3) 361–375. DOI:<a href=\"https://doi.org/10.1080/14656566.2021.2010706\">10.1080/14656566.2021.2010706</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34882041/\">https://pubmed.ncbi.nlm.nih.gov/34882041</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XX08;
